Skip to main content
Erschienen in: American Journal of Clinical Dermatology 2/2000

01.03.2000 | Disease Management

Management of Seborrheic Dermatitis and Pityriasis Versicolor

verfasst von: Dr Jan Faergemann

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2000

Einloggen, um Zugang zu erhalten

Abstract

Pityriasis (tinea) versicolor and seborrheic dermatitis are two very common skin diseases. Pityriasis versicolor is a chronic superficial fungal disease usually located on the upper trunk, neck, or upper arms. In pityriasis versicolor, the lipophilic yeast Malassezia (also know as Pityrosporum ovale or P. orbiculare) changes from the blastospore form to the mycelial form under the influence of predisposing factors. The most important exogenous factors are high temperatures and a high relative humidity which probably explain why pityriasis versicolor is more common in the tropics. The most important endogenous factors are greasy skin, hyperhidrosis, hereditary factors, corticosteroid treatment and immunodeficiency. There are many ways of treating pityriasis versicolor topically. Options include propylene glycol, ketoconazole shampoo, zinc pyrithione shampoo, ciclopiroxamine, selenium sulfide, and topical antifungals. In difficult cases, short term treatment with fluconazole or itraconazole is effective and well tolerated. To avoid recurrence a prophylactic treatment regimen is mandatory.
Seborrheic dermatitis is characterized by red scaly lesions predominantly located on the scalp, face and upper trunk. There are now many studies indicating that Malassezia plays an important role in this condition. Even a normal number of Malassezia will start an inflammatory reaction. Mild corticosteroids are effective in the treatment of seborrheic dermatitis. However, the disease recurs quickly, often within just a few days. Antifungal therapy is effective in the treatment of seborrheic dermatitis and, because it reduces the number of Malassezia, the time to recurrence is increased compared with treatment with corticosteroids. Antifungal therapy should be the primary treatment of this disease.
Literatur
1.
Zurück zum Zitat Gordon M.A. The lipophilic microflora of the skin. Mycologia 1951; 43: 524–534CrossRef Gordon M.A. The lipophilic microflora of the skin. Mycologia 1951; 43: 524–534CrossRef
2.
Zurück zum Zitat Roberts S.O.B. Pityrosporum orbiculare: incidence and distribution on clinical normal skin. Br J Dermatol 1969; 81: 264–269PubMedCrossRef Roberts S.O.B. Pityrosporum orbiculare: incidence and distribution on clinical normal skin. Br J Dermatol 1969; 81: 264–269PubMedCrossRef
3.
Zurück zum Zitat Faergemann J, Aly R, Maibach HI. Quantitative variations in distribution of Pityrosporum orbiculare on clinically normal skin. Acta Derm Venereol (Stockh) 983; 63: 346–8 Faergemann J, Aly R, Maibach HI. Quantitative variations in distribution of Pityrosporum orbiculare on clinically normal skin. Acta Derm Venereol (Stockh) 983; 63: 346–8
4.
Zurück zum Zitat Faergemann J., Fredriksson T. Age incidence of Pityrosporum orbiculare on human skin. Acta Derm Venereol (Stockh) 1980; 60: 531–533 Faergemann J., Fredriksson T. Age incidence of Pityrosporum orbiculare on human skin. Acta Derm Venereol (Stockh) 1980; 60: 531–533
5.
Zurück zum Zitat Gueho E., Midgley G., Guillot J. The genus Malassezia with description of four new species. Antonie v Leuwenhoek 1996; 69: 337–355CrossRef Gueho E., Midgley G., Guillot J. The genus Malassezia with description of four new species. Antonie v Leuwenhoek 1996; 69: 337–355CrossRef
6.
Zurück zum Zitat Guillot J., Guého E., Lesourd M., et al. Identification of Malassezia species — a practical approach. J Mycol Méd 1996; 6: 103–110 Guillot J., Guého E., Lesourd M., et al. Identification of Malassezia species — a practical approach. J Mycol Méd 1996; 6: 103–110
7.
Zurück zum Zitat Faergemann J. Lipophilic yeasts in skin disease. Semin Dermatol 1985; 4: 173–184 Faergemann J. Lipophilic yeasts in skin disease. Semin Dermatol 1985; 4: 173–184
8.
9.
Zurück zum Zitat Faergemann J. Pityrosporum infections. In: Elewski B.E., editor. Cutaneous fungal infections. New York: Igaku-Shoin, 1992: 69–83 Faergemann J. Pityrosporum infections. In: Elewski B.E., editor. Cutaneous fungal infections. New York: Igaku-Shoin, 1992: 69–83
10.
Zurück zum Zitat Faergemann J. Tinea versicolor (Pityriasis versicolor). In: Demis D.J., editor. Clinical Dermatology. Philadelphia: Lippincott-Raven, 1995: 1–9 Faergemann J. Tinea versicolor (Pityriasis versicolor). In: Demis D.J., editor. Clinical Dermatology. Philadelphia: Lippincott-Raven, 1995: 1–9
11.
Zurück zum Zitat Faergemann J., Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1989; 60: 92–93 Faergemann J., Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1989; 60: 92–93
12.
Zurück zum Zitat Fredriksson T. Topical treatment with BAY b 5097, a new broad spectrum antimycotic agent. Br J Dermatol 1972; 86: 628–630PubMedCrossRef Fredriksson T. Topical treatment with BAY b 5097, a new broad spectrum antimycotic agent. Br J Dermatol 1972; 86: 628–630PubMedCrossRef
13.
Zurück zum Zitat Svejgaard E. Double-blind trial of miconazole in dermatomycosis. Acta Derma Venereol (Stockh) 1973; 53: 497–499 Svejgaard E. Double-blind trial of miconazole in dermatomycosis. Acta Derma Venereol (Stockh) 1973; 53: 497–499
14.
Zurück zum Zitat Swartz K.J., Moch T.H., Kenzelmann M. Poloklinische Prüfung von Econazole bei 594 Fallen von Hautmykosen. Dtsch Med Wochenschr 1975; 100: 1497–1500CrossRef Swartz K.J., Moch T.H., Kenzelmann M. Poloklinische Prüfung von Econazole bei 594 Fallen von Hautmykosen. Dtsch Med Wochenschr 1975; 100: 1497–1500CrossRef
15.
Zurück zum Zitat Faergemann J., Fredriksson T. An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor. Cutis 1980; 25: 667–669PubMed Faergemann J., Fredriksson T. An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor. Cutis 1980; 25: 667–669PubMed
16.
Zurück zum Zitat Albright S.D., Hitch J.M. Rabbit treatment of tinea versicolor with selenium sulphide. Arch Dermatol 1966; 93: 460–461PubMedCrossRef Albright S.D., Hitch J.M. Rabbit treatment of tinea versicolor with selenium sulphide. Arch Dermatol 1966; 93: 460–461PubMedCrossRef
17.
Zurück zum Zitat Hernandez-Perez E. A comparison between one and two week’s treatment with bifonazole in pityriasis versicolor. J Am Acad Dermatol 1986; 14: 561–564PubMedCrossRef Hernandez-Perez E. A comparison between one and two week’s treatment with bifonazole in pityriasis versicolor. J Am Acad Dermatol 1986; 14: 561–564PubMedCrossRef
18.
Zurück zum Zitat Savin R.C., Horwitz S.N. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15: 500–503PubMedCrossRef Savin R.C., Horwitz S.N. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15: 500–503PubMedCrossRef
19.
Zurück zum Zitat Aste N., Pau M., Pinna A.L., et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353–357PubMedCrossRef Aste N., Pau M., Pinna A.L., et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353–357PubMedCrossRef
20.
Zurück zum Zitat Faergemann J., Hersle K., Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Dermatol 1997; 194 Suppl. 1: 19–21CrossRef Faergemann J., Hersle K., Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Dermatol 1997; 194 Suppl. 1: 19–21CrossRef
21.
Zurück zum Zitat Vermeer B.J., Staats C.C.G. The efficacy of a topical application application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo controlled study. Dermatol 1997; 194 Suppl. 1: 22–24CrossRef Vermeer B.J., Staats C.C.G. The efficacy of a topical application application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo controlled study. Dermatol 1997; 194 Suppl. 1: 22–24CrossRef
22.
Zurück zum Zitat Corte M., Jung K., Linker U., et al. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32: 200–203PubMedCrossRef Corte M., Jung K., Linker U., et al. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32: 200–203PubMedCrossRef
23.
Zurück zum Zitat Rekacewicz I., Guillaume J.C., Benkhraba F., et al. A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor. Ann Dermatol Venereol 1990; 117: 709–711PubMed Rekacewicz I., Guillaume J.C., Benkhraba F., et al. A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor. Ann Dermatol Venereol 1990; 117: 709–711PubMed
24.
Zurück zum Zitat Lange D.S., Richards H.M., Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo- controlled study. J Am Acad Dermatol 1998; 39: 944–950PubMedCrossRef Lange D.S., Richards H.M., Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo- controlled study. J Am Acad Dermatol 1998; 39: 944–950PubMedCrossRef
25.
Zurück zum Zitat Jones H.E. Ketoconazole today. A review of clinical experience. Manchester, England: ADIS Press, 1987 Jones H.E. Ketoconazole today. A review of clinical experience. Manchester, England: ADIS Press, 1987
26.
Zurück zum Zitat Faergemann J., Djärv L.: Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis 1982; 30: 542–545PubMed Faergemann J., Djärv L.: Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis 1982; 30: 542–545PubMed
27.
Zurück zum Zitat Hay R.J., Midgley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9: 571–573PubMedCrossRef Hay R.J., Midgley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9: 571–573PubMedCrossRef
28.
Zurück zum Zitat Rausch L.J., Jacobs P.H. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1964; 34: 470–471 Rausch L.J., Jacobs P.H. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1964; 34: 470–471
29.
Zurück zum Zitat Shemer A., Nathansohn N., Kaplan B., et al. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treat 1999; 10: 19–23CrossRef Shemer A., Nathansohn N., Kaplan B., et al. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treat 1999; 10: 19–23CrossRef
30.
Zurück zum Zitat Delescluse J. Itraconazole in tinea versicolor. A review. J Am Acad Dermatol 1990; 23: 551–554PubMedCrossRef Delescluse J. Itraconazole in tinea versicolor. A review. J Am Acad Dermatol 1990; 23: 551–554PubMedCrossRef
31.
Zurück zum Zitat Faergemann J. Treatment of pityriasis versicolor with itraconazole. A doubleblind placebo-controlled study. Mykoses 1988; 31: 377–379CrossRef Faergemann J. Treatment of pityriasis versicolor with itraconazole. A doubleblind placebo-controlled study. Mykoses 1988; 31: 377–379CrossRef
32.
Zurück zum Zitat Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol (Stockh) 1992; 72: 74–75 Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol (Stockh) 1992; 72: 74–75
33.
Zurück zum Zitat Amer M.A. Fluconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 938–946CrossRef Amer M.A. Fluconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 938–946CrossRef
34.
Zurück zum Zitat Burton J.L., Holden C.A. Seborrhoeic dermatitis. In: Champion R.H., Burton J.L., Burna D.A., et al., editors. Textbook of Dermatology (ed 6). Oxford: Blackwell Scientific Publications, 1998: pp 638–643 Burton J.L., Holden C.A. Seborrhoeic dermatitis. In: Champion R.H., Burton J.L., Burna D.A., et al., editors. Textbook of Dermatology (ed 6). Oxford: Blackwell Scientific Publications, 1998: pp 638–643
35.
Zurück zum Zitat Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Dactacort), miconazole and hydrocrotisone. Br J Dermatol 1986; 114: 695–700PubMedCrossRef Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Dactacort), miconazole and hydrocrotisone. Br J Dermatol 1986; 114: 695–700PubMedCrossRef
36.
Zurück zum Zitat Bergbrant I.-M. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh) 1991; 167: 1–36 Bergbrant I.-M. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh) 1991; 167: 1–36
37.
Zurück zum Zitat Sohnle P.G., Collins-Lech C. Activation of complement by Pityrosporum orbiculare. J Invest Dermatol 1983; 80: 93–97PubMedCrossRef Sohnle P.G., Collins-Lech C. Activation of complement by Pityrosporum orbiculare. J Invest Dermatol 1983; 80: 93–97PubMedCrossRef
38.
Zurück zum Zitat Midgley G., Hay R.J. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Mycol Méd 1988; 17: 267–276 Midgley G., Hay R.J. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Mycol Méd 1988; 17: 267–276
39.
Zurück zum Zitat Neuber K., Kröger S., Gruseck E., et al. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN?) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996; 288: 532–536PubMed Neuber K., Kröger S., Gruseck E., et al. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN?) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996; 288: 532–536PubMed
40.
Zurück zum Zitat Wikler J.R., Trago E., de Haan P., et al. Cell-mediated deficiency to Pityrosporum orbiculare in patients with seborrhoeic dermatitis [abstract]. ESDR-JSID-SID Tricontinental Meeting; 1989 Apr 26-30; Washington DC Wikler J.R., Trago E., de Haan P., et al. Cell-mediated deficiency to Pityrosporum orbiculare in patients with seborrhoeic dermatitis [abstract]. ESDR-JSID-SID Tricontinental Meeting; 1989 Apr 26-30; Washington DC
41.
Zurück zum Zitat Ashbee H.R., Ingham E., Holland K.T, et al. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls. Exp Dermatol 1994; 3: 106–112PubMedCrossRef Ashbee H.R., Ingham E., Holland K.T, et al. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls. Exp Dermatol 1994; 3: 106–112PubMedCrossRef
42.
Zurück zum Zitat Bergbrant I.-M., Andersson B., Faergemann J. Cell-mediated immunity to Pityrosporum ovale in patients with seborrhoeic dermatitis and pityriasis versicolor. Cin Exp Dermatol 1999; 24: 402–406CrossRef Bergbrant I.-M., Andersson B., Faergemann J. Cell-mediated immunity to Pityrosporum ovale in patients with seborrhoeic dermatitis and pityriasis versicolor. Cin Exp Dermatol 1999; 24: 402–406CrossRef
43.
Zurück zum Zitat Pearry M.E., Sharpe G.R. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254–263CrossRef Pearry M.E., Sharpe G.R. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254–263CrossRef
44.
Zurück zum Zitat Bergbrant I.-M., Johansson S., Robbins D., et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331–338PubMedCrossRef Bergbrant I.-M., Johansson S., Robbins D., et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331–338PubMedCrossRef
45.
Zurück zum Zitat Kieffer M., Bergbrant I.-M., Faergemann J., et al. Skov patients with atopic dermatitis and seborrhoeic dermatitis. J Am Acad Dermatol 1990; 22: 739–742PubMedCrossRef Kieffer M., Bergbrant I.-M., Faergemann J., et al. Skov patients with atopic dermatitis and seborrhoeic dermatitis. J Am Acad Dermatol 1990; 22: 739–742PubMedCrossRef
46.
Zurück zum Zitat Kesavan S., Walters C.E., Holland K.T, et al. The effects of Malassezia on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol 1998; 36: 97–106PubMed Kesavan S., Walters C.E., Holland K.T, et al. The effects of Malassezia on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol 1998; 36: 97–106PubMed
47.
Zurück zum Zitat Piérard-Franshimont C., Arrese J.E., Piérard G.E. Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995; 4: 14–49CrossRef Piérard-Franshimont C., Arrese J.E., Piérard G.E. Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995; 4: 14–49CrossRef
48.
Zurück zum Zitat Romani L., Bistoni F., Puccetti P. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem Immunol 1997; 68: 110–135PubMedCrossRef Romani L., Bistoni F., Puccetti P. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem Immunol 1997; 68: 110–135PubMedCrossRef
49.
Zurück zum Zitat Gulay Z., Imir T. Anti-candidial activity of natural killer (NK) an lymphokine activated killer (LAK) lymphocytes in vitro. Immunobiol 1996; 95: 220–230CrossRef Gulay Z., Imir T. Anti-candidial activity of natural killer (NK) an lymphokine activated killer (LAK) lymphocytes in vitro. Immunobiol 1996; 95: 220–230CrossRef
50.
Zurück zum Zitat Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111: 235–242PubMedCrossRef Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111: 235–242PubMedCrossRef
51.
Zurück zum Zitat Skinner R.B., Noah P.W., Taylor R.M., et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 2: 852–857CrossRef Skinner R.B., Noah P.W., Taylor R.M., et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 2: 852–857CrossRef
52.
Zurück zum Zitat Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. Acta Dermato Venereol (Stockh) 1990; 70: 171–172 Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. Acta Dermato Venereol (Stockh) 1990; 70: 171–172
53.
Zurück zum Zitat Ford G.P., Farr P.M., Ive F.A., et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603–607PubMedCrossRef Ford G.P., Farr P.M., Ive F.A., et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603–607PubMedCrossRef
54.
Zurück zum Zitat Stratigos I.D., Katamboas A., Antoniu C.H., et al. Ketoconazole 2% cream versus 1% hydrocortisone cream in the treatment of seborrhoeic dermatitis: a doubleblind comparative study. J Am Acad Dermatol 1988; 19: 850–853PubMedCrossRef Stratigos I.D., Katamboas A., Antoniu C.H., et al. Ketoconazole 2% cream versus 1% hydrocortisone cream in the treatment of seborrhoeic dermatitis: a doubleblind comparative study. J Am Acad Dermatol 1988; 19: 850–853PubMedCrossRef
55.
Zurück zum Zitat Marks R., Pears A.D., Walker A.P. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415–422PubMedCrossRef Marks R., Pears A.D., Walker A.P. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415–422PubMedCrossRef
56.
Zurück zum Zitat Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. Cutis 1988; 42: 69–71PubMed Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. Cutis 1988; 42: 69–71PubMed
57.
Zurück zum Zitat Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses 1989; 32: 309–311PubMedCrossRef Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses 1989; 32: 309–311PubMedCrossRef
58.
Zurück zum Zitat Shuttleworth D., Squire R.A., Boorman G.C., et al. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–162CrossRef Shuttleworth D., Squire R.A., Boorman G.C., et al. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–162CrossRef
59.
Zurück zum Zitat Zeharia A., Mimouni M., Fogel D. Treatment with bifonazole shampoo for scalp seborrhea in infants and young children. Ped Dermatol 1996; 13: 151–153CrossRef Zeharia A., Mimouni M., Fogel D. Treatment with bifonazole shampoo for scalp seborrhea in infants and young children. Ped Dermatol 1996; 13: 151–153CrossRef
60.
Zurück zum Zitat Pari T., Pulimood S., Jacob M., et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998; 10: 89–90PubMedCrossRef Pari T., Pulimood S., Jacob M., et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998; 10: 89–90PubMedCrossRef
61.
Zurück zum Zitat Veen A.J., Prevoo R.L.M.A., Velders A.J., et al. Betamethasone-17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults. J Dermatol Treat 1998; 9: 239–245CrossRef Veen A.J., Prevoo R.L.M.A., Velders A.J., et al. Betamethasone-17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults. J Dermatol Treat 1998; 9: 239–245CrossRef
Metadaten
Titel
Management of Seborrheic Dermatitis and Pityriasis Versicolor
verfasst von
Dr Jan Faergemann
Publikationsdatum
01.03.2000
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2000
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200001020-00001

Weitere Artikel der Ausgabe 2/2000

American Journal of Clinical Dermatology 2/2000 Zur Ausgabe

Disease Management

Management of Hirsutism

Adis New Drug Profile

Topical Aminolevulinic Acid HCL

Practical Dermatology

Diagnosing Superficial Mycoses

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.